Bulk Pharmaceutical API Sources for PROMACTA

Bulk Pharmaceutical API Sources for PROMACTA

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-1566
MedChemexpress MCE		HY-15306A
Sun-shine Chemical		Eltrombopag olamine
AKos Consulting & Solutions		AKOS025396658
Hangzhou APIChem Technology		AC-26286

PROMACTA Bulk API Sourcing Landscape

Last updated: February 19, 2026

PROMACTA, the brand name for eltrombopag, is a thrombopoietin receptor agonist used to treat thrombocytopenia. Identifying reliable bulk Active Pharmaceutical Ingredient (API) sources is critical for generic manufacturers and pharmaceutical companies seeking to ensure consistent supply chains and competitive pricing for this vital therapeutic. This analysis details the current landscape of PROMACTA API sourcing, focusing on key manufacturers, geographical distribution, and emerging trends.

Who Manufactures PROMACTA API?

Several API manufacturers globally are capable of producing eltrombopag. These manufacturers vary in scale, regulatory compliance, and market reach.

Key API Manufacturers for Eltrombopag:

• Lupin Ltd.: An established Indian pharmaceutical company with significant API manufacturing capabilities. Lupin has a history of developing and manufacturing complex APIs, including those for oncology and immunology. Their regulatory filings and production capacity position them as a notable supplier.
• Dr. Reddy's Laboratories Ltd.: Another major Indian pharmaceutical player with a strong focus on API development and manufacturing. Dr. Reddy's has a robust global presence and adheres to stringent international quality standards, including US FDA and EMA approvals.
• Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company, Sun Pharma also operates extensive API manufacturing facilities. They are known for their backward integration and ability to produce a wide range of APIs, including those for critical care medications.
• Alkem Laboratories Ltd.: A significant Indian pharmaceutical company with a growing API portfolio. Alkem has been expanding its manufacturing capacity and regulatory footprint, making it a potential supplier for eltrombopag.
• Divi's Laboratories Ltd.: A prominent Indian API manufacturer, Divi's is known for its large-scale custom synthesis and manufacturing services. While often operating behind the scenes as a contract manufacturer, their capacity and quality standards make them a potential source for key intermediates and the final API.
• Various Chinese Manufacturers: Numerous Chinese API manufacturers, including both large, publicly traded entities and smaller specialized firms, are involved in the production of eltrombopag or its key intermediates. These companies often offer competitive pricing but require thorough due diligence regarding quality control and regulatory adherence. Specific company names in this segment can fluctuate due to market dynamics and intellectual property considerations.

These manufacturers typically operate under Good Manufacturing Practices (GMP) and have obtained or are seeking approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others relevant to their target markets.

What is the Geographical Distribution of PROMACTA API Production?

The production of eltrombopag API is concentrated in specific geographical regions, primarily driven by established pharmaceutical manufacturing ecosystems and cost advantages.

Primary API Manufacturing Hubs:

• India: Holds a dominant position in global API manufacturing due to its skilled workforce, robust regulatory framework (increasingly aligned with international standards), and cost-effective production environment. Companies like Lupin, Dr. Reddy's, Sun Pharma, Alkem, and Divi's are headquartered and operate significant manufacturing facilities in India.
• China: Remains a critical global supplier for many APIs, including intermediates and finished eltrombopag API. Chinese manufacturers contribute significantly to the global supply chain, often specializing in cost-competitive production. Regulatory oversight and quality assurance are key considerations when sourcing from China.
• Europe: While less dominant in bulk API production compared to Asia, some European companies may be involved in niche manufacturing or the production of highly specialized intermediates. Their strength often lies in advanced manufacturing technologies and stringent quality control.
• North America: API manufacturing in North America for eltrombopag is less prevalent for bulk production compared to the Asian market. Companies in this region may focus on specialized or high-value APIs, or contract manufacturing for specific market needs, often maintaining very high regulatory standards.

The reliance on India and China for bulk API production presents opportunities for competitive pricing but also necessitates robust supply chain management and quality assurance protocols to mitigate risks.

What are the Key Regulatory Considerations for API Sourcing?

Sourcing PROMACTA API requires strict adherence to regulatory standards to ensure product safety, efficacy, and market compliance.

Critical Regulatory Aspects:

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA in the U.S., EDQM in Europe). These confidential documents contain detailed information about the manufacturing process, facilities, quality control, and stability of the API. Generic drug applicants reference these DMFs in their marketing authorization applications.
• GMP Compliance: All API manufacturing facilities must comply with current Good Manufacturing Practices (cGMP) as defined by relevant regulatory bodies. Regular inspections by agencies like the FDA and EMA verify compliance.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines (e.g., ICH Q7 for API GMP) is essential for global market acceptance.
• Site Inspections and Audits: Pharmaceutical companies sourcing API must conduct thorough due diligence, including site inspections and audits of potential manufacturers, to verify quality systems and regulatory compliance.
• Impurity Profiling and Control: Comprehensive understanding and control of process-related impurities and degradation products are critical. This includes detailed analytical method validation and routine testing.
• Geographic Origin: While not a direct regulatory requirement, the country of origin can impact import regulations, tariffs, and perceived supply chain risks.

Manufacturers with a strong regulatory track record and successful DMF submissions are generally preferred for consistent and compliant API supply.

What are the Market Dynamics and Pricing Factors?

The pricing of eltrombopag API is influenced by several market factors, including manufacturing costs, patent expiries, generic competition, and supply chain security.

Factors Influencing API Pricing:

• Manufacturing Scale and Efficiency: Larger production volumes generally lead to lower per-unit costs due to economies of scale. Manufacturers with optimized synthetic routes and efficient processes have a cost advantage.
• Raw Material Costs: The cost and availability of key starting materials and intermediates directly impact the final API price. Fluctuations in commodity chemical prices can affect eltrombopag API costs.
• Regulatory Compliance Costs: Meeting stringent GMP requirements, undergoing regular audits, and maintaining extensive documentation add to manufacturing costs. Manufacturers with established, compliant facilities may have higher overheads but offer greater reliability.
• Generic Competition: As patents for PROMACTA expire or are successfully challenged, the entry of multiple generic manufacturers intensifies competition, driving down API prices. The anticipation of market entry often leads to price negotiations.
• Intellectual Property Landscape: While the primary patents for eltrombopag may have expired or are nearing expiry in key markets, process patents and polymorph patents can still influence manufacturing freedom and cost.
• Supply Chain Stability and Geopolitics: Events such as trade disputes, natural disasters, or global health crises can disrupt supply chains, leading to increased prices due to scarcity or heightened logistical costs. Ensuring a stable supply often involves qualifying multiple sources.
• Demand: The therapeutic need for eltrombopag and the prevalence of conditions it treats directly influence API demand and, consequently, pricing.

Pricing for eltrombopag API can range significantly based on the manufacturer's location, regulatory status, production volume, and the buyer's negotiation leverage. Indicative pricing for generic APIs often falls within a range that allows for a profitable finished dosage form in a competitive market. For example, bulk eltrombopag API prices can range from USD $150 to $400 per kilogram, subject to substantial market volatility and negotiation.

What are the Future Trends in PROMACTA API Sourcing?

The sourcing landscape for eltrombopag API is evolving, influenced by technological advancements, regulatory shifts, and supply chain resilience strategies.

Emerging Trends:

• Increased Focus on Supply Chain Diversification: Pharmaceutical companies are increasingly looking to diversify their API sources beyond traditional hubs to mitigate geopolitical risks and single-source dependency. This may involve identifying secondary suppliers in different geographies.
• Advancements in Continuous Manufacturing: The pharmaceutical industry is exploring continuous manufacturing processes for APIs. If successfully applied to eltrombopag, this could lead to more efficient, consistent, and potentially lower-cost production.
• Green Chemistry Initiatives: Growing environmental concerns are pushing API manufacturers to adopt more sustainable and environmentally friendly synthetic routes. This includes reducing solvent usage, waste generation, and energy consumption.
• Digitalization and Traceability: Enhanced use of digital technologies for supply chain management, traceability, and quality control is becoming more important. Blockchain and IoT solutions are being explored to improve transparency and security.
• Outsourcing of Specialized Steps: While bulk API production may remain concentrated in traditional hubs, some companies might outsource specific complex synthesis steps or intermediate manufacturing to specialized Contract Development and Manufacturing Organizations (CDMOs) with niche expertise.
• Stricter Regulatory Scrutiny: Regulatory agencies are increasing their scrutiny of API quality and supply chain integrity, particularly concerning imports. This demands higher standards from manufacturers and robust supplier qualification processes.

These trends indicate a move towards more resilient, efficient, and sustainable API sourcing strategies for eltrombopag.

---

Key Takeaways

• Dominant Manufacturers: Key eltrombopag API manufacturers are primarily based in India, including Lupin, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Alkem Laboratories, and Divi's Laboratories. Chinese manufacturers also play a significant role.
• Regulatory Imperatives: Strict adherence to GMP, comprehensive DMF filings, and successful regulatory agency inspections (FDA, EMA) are non-negotiable for API sourcing.
• Pricing Variables: API pricing is influenced by manufacturing scale, raw material costs, regulatory compliance overhead, generic market competition, and supply chain stability.
• Supply Chain Diversification: Future sourcing strategies will likely prioritize diversification to enhance supply chain resilience and mitigate geopolitical risks.
• Technological Evolution: Advancements in continuous manufacturing and green chemistry are expected to shape future API production methods for eltrombopag.

---

Frequently Asked Questions

What is the primary function of PROMACTA (eltrombopag)?

PROMACTA (eltrombopag) is a thrombopoietin receptor agonist that stimulates the production of platelets by the bone marrow. It is used to treat chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to corticosteroids, immunoglobulins, or platelet apheresis. It is also indicated for thrombocytopenia in patients with chronic hepatitis C to allow for the initiation of interferon-based therapy.

Are there significant patent expiries impacting eltrombopag API sourcing?

The primary compound patent for eltrombopag has expired in major markets. However, secondary patents related to specific manufacturing processes, formulations, or polymorphs may still be in effect and can influence the freedom to operate for generic API manufacturers. Companies must conduct thorough patent landscape analyses.

How can a pharmaceutical company ensure the quality and reliability of an eltrombopag API supplier?

Ensuring quality and reliability involves a multi-faceted approach including thorough due diligence, on-site audits of manufacturing facilities, verification of regulatory compliance (e.g., FDA/EMA inspection history, DMF status), assessment of their quality management system, evaluation of their impurity profiling and control strategies, and establishing clear supply agreements with robust quality clauses.

What are the typical lead times for sourcing bulk eltrombopag API?

Lead times for bulk eltrombopag API can vary significantly depending on the manufacturer's existing production schedule, order volume, and geographical location. Generally, lead times can range from 3 to 9 months from order placement to delivery, assuming the manufacturer has available capacity and raw materials. It is advisable to engage with suppliers well in advance of anticipated needs.

Beyond India and China, are there any other significant regions emerging for eltrombopag API production?

While India and China remain the dominant manufacturing hubs, there is a trend towards exploring diversified sourcing. Some companies are investigating niche API manufacturers in Eastern Europe or specialized contract manufacturing organizations (CMOs) in North America and Europe for specific intermediates or highly regulated API segments. However, for bulk, cost-competitive production, the primary focus remains on Asia.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs [2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines [3] (Confidential market data and industry reports not publicly linkable)